TP53 and colorectal cancer: This hypothesis may be consistent with the consensus that mutations in TP53 are relatively infrequent in endometrioid-type EC (Yeramian et al. 2013), which are similarly regarded as rare in the MIN pathway of colorectal cancer (Ionov et al. 1993; Salahshor et al. 1999; Samowitz et al. 2001; Simms et al. 1998).